Construction of genetically marked Vibrio cholerae O1 vaccine strains - PubMed (original) (raw)
Construction of genetically marked Vibrio cholerae O1 vaccine strains
J M Ketley et al. FEMS Microbiol Lett. 1993.
Erratum in
- FEMS Microbiol Lett 1998 Jun 15;163(2):269
Abstract
Attenuated Vibrio cholerae O1 vaccine strains lacking the gene encoding the A subunit of cholera toxin have proven efficacious in preventing experimental cholera. As these strains move from closed, contained testing environments to large-scale field trials, a readily assayable phenotypic trait to distinguish a vaccine strain from wild-type V. cholerae O1 is desirable. We have constructed three derivatives of the attenuated V. cholerae strain CVD 103 which carry a mercury resistance or urease marker in the hlyA gene. CVD 103-HgR was constructed using a protracted marker-exchange procedure; this strain was found to have somewhat lowered colonisation efficiency in infant mice in comparison to its parent strain, CVD 103. The insertion of the resistance marker was repeated using a suicide vector system; CVD 103-HgR2 was found to colonise infant mice as efficiently as CVD 103. Strain CVD 103-UR, in which sequences encoding urease were inserted using a suicide vector, also colonised infant mice as well as CVD 103. The genetically marked strains CVD 103-HgR, CVD 103-HgR2 and CVD 103-UR form the basis for a generation of defined oral vaccines that may give single-dose, long-lasting protection to populations at risk from cholera.
Similar articles
- A review of the current status of enteric vaccines.
Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review. - Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR.
Kaper JB, Michalski J, Ketley JM, Levine MM. Kaper JB, et al. Infect Immun. 1994 Apr;62(4):1480-3. doi: 10.1128/iai.62.4.1480-1483.1994. Infect Immun. 1994. PMID: 8132356 Free PMC article. - CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.
Michalski J, Galen JE, Fasano A, Kaper JB. Michalski J, et al. Infect Immun. 1993 Oct;61(10):4462-8. doi: 10.1128/iai.61.10.4462-4468.1993. Infect Immun. 1993. PMID: 8406837 Free PMC article. - Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains.
Benítez JA, Silva AJ, Rodríguez BL, Fando R, Campos J, Robert A, García H, García L, Pérez JL, Oliva R, Torres CA, Ledón T. Benítez JA, et al. Arch Med Res. 1996 Autumn;27(3):275-83. Arch Med Res. 1996. PMID: 8854382 - Cholera vaccines.
Ryan ET, Calderwood SB. Ryan ET, et al. Clin Infect Dis. 2000 Aug;31(2):561-5. doi: 10.1086/313951. Epub 2000 Sep 7. Clin Infect Dis. 2000. PMID: 10987721 Review.
Cited by
- An overview of VaxchoraTM, a live attenuated oral cholera vaccine.
Saluja T, Mogasale VV, Excler JL, Kim JH, Mogasale V. Saluja T, et al. Hum Vaccin Immunother. 2020;16(1):42-50. doi: 10.1080/21645515.2019.1644882. Epub 2019 Sep 20. Hum Vaccin Immunother. 2020. PMID: 31339792 Free PMC article. - Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.
Jones CH, Hakansson AP, Pfeifer BA. Jones CH, et al. J Mater Chem B. 2014;46:8053-8068. doi: 10.1039/C4TB01058B. Epub 2014 Sep 12. J Mater Chem B. 2014. PMID: 29887986 Free PMC article. - Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM. Sow SO, et al. Clin Vaccine Immunol. 2017 Dec 5;24(12):e00265-17. doi: 10.1128/CVI.00265-17. Print 2017 Dec. Clin Vaccine Immunol. 2017. PMID: 29021299 Free PMC article. Clinical Trial. - Antigen Localization Influences the Magnitude and Kinetics of Endogenous Adaptive Immune Response to Recombinant Salmonella Vaccines.
Sevastsyanovich YR, Withers DR, Marriott CL, Morris FC, Wells TJ, Browning DF, Beriotto I, Ross E, Ali HO, Wardius CA, Cunningham AF, Henderson IR, Rossiter AE. Sevastsyanovich YR, et al. Infect Immun. 2017 Nov 17;85(12):e00593-17. doi: 10.1128/IAI.00593-17. Print 2017 Dec. Infect Immun. 2017. PMID: 28893919 Free PMC article. - The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB. Mayo-Smith LM, et al. Clin Vaccine Immunol. 2017 Jan 5;24(1):e00470-16. doi: 10.1128/CVI.00470-16. Print 2017 Jan. Clin Vaccine Immunol. 2017. PMID: 27847368 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials